Related Experiment Videos

Does ceftazidime or latamoxef affect the phagocytic capabilities of human granulocytes?

J Prokopowicz1, M Dabrowska, J Wysocka

  • 1Department of Laboratory Clinical Diagnostics, Medical School, Białystok, Poland.

Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1987
PubMed

Insights

Latamoxef and Ceftazidime treatments for pneumonia improved granulocyte and plasma bactericidal activity. Both antibiotics showed no negative impact on granulocyte phagocytic capacity, indicating safe therapeutic use.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Immunology

Background:

  • Pneumonia treatment requires effective antibiotics with minimal side effects.
  • Assessing antibiotic impact on immune cell function is crucial for understanding therapeutic outcomes.

Purpose of the Study:

  • To compare the effects of Latamoxef and Ceftazidime on pneumonia patients.
  • To evaluate the impact of these antibiotics on granulocyte function and bactericidal activity.

Main Methods:

  • Comparative study involving 14 patients treated with Latamoxef and 16 with Ceftazidime.
  • Assessment of side effects, plasma bactericidal activity, and granulocyte functions including phagocytosis and NBT reduction.

Main Results:

  • Both Latamoxef and Ceftazidime increased bactericidal activity in granulocytes and plasma.
  • A decrease in resting granulocyte bactericidal activity and elevated NBT reduction were observed.
  • No harmful effects on granulocyte phagocytic capacity were noted for either drug.

Conclusions:

  • Latamoxef and Ceftazidime are effective in treating pneumonia.
  • These antibiotics enhance key immune functions without compromising granulocyte phagocytosis.

Related Concept Videos